216 related articles for article (PubMed ID: 31723730)
1. Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies.
Naymagon L; Mascarenhas J
Hemasphere; 2017 Dec; 1(1):e1. PubMed ID: 31723730
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
3. State-of-the-Art Review on Myelofibrosis Therapies.
Wang F; Qiu T; Wang H; Yang Q
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
[TBL] [Abstract][Full Text] [Related]
4. Anemia in myelofibrosis: Current and emerging treatment options.
Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
[TBL] [Abstract][Full Text] [Related]
5. Treatment and management of myelofibrosis in the era of JAK inhibitors.
Keohane C; Radia DH; Harrison CN
Biologics; 2013; 7():189-98. PubMed ID: 23990704
[TBL] [Abstract][Full Text] [Related]
6. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
Sastow D; Mascarenhas J; Tremblay D
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
Waksal JA; Mascarenhas J
Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
[TBL] [Abstract][Full Text] [Related]
8. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
Mughal TI; Vaddi K; Sarlis NJ; Verstovsek S
Int J Gen Med; 2014; 7():89-101. PubMed ID: 24501543
[TBL] [Abstract][Full Text] [Related]
9. Myelofibrosis: diagnosis and treatment.
Barranco-Lampón G; Martínez-Castro R; Arana-Luna L; Álvarez-Vera JL; Rojas-Castillejos F; Peñaloza-Ramírez R; Carballo-Zarate AA; Olarte-Carrillo I; Minamy JI; López-Salazar J; Navarrete JJ; Espinosa-Partida A; Ventura-Enríquez Y; Ruiz-Contreras JI; Aguirre-Reyes OG; Anaya-Cuéllar I; Aguilar-Luévano J; Díaz-Ramírez HF; Herrera-Olivares W; Aguilar-Hidalgo JA; Alcívar-Cedeño LM; Hernández-Caballero Á; Galaz-Cordero LE; Peña-Celaya JA; Báez-Islas PE; Bates-Martín RA; Cano-León AML; Espitia-Ríos ME; Barbosa D; Morales-Adrián J; Pacheco MJ; Delgado-López N; Neme-Yunes Y; Moralws-Hernández AE; Mújica-Martínez A; Pérez-Lizardi AB; Pérez-Gómez KD; Barragán-Ibáñez G; Martínez A; Flores-Ordúñez K; Ramírez-Hoyos P; Rosales-López MLÁ; Acosta-Maldonado BL; Jiménez-Ochoa MA; Garzón-Velásquez KB; Hernández-Ruiz E; McNally-Guillén BM; Saucedo-Montes EE; Aguilar-Andrade C; Vivas-Arteaga CL; Guerra-Alarcón LV; Milán-Salvatierra AI; Campa-Monroy DI; Cota-Rangel X; Estrada-Domínguez P; García-Camacho AS; García-Castillo C; Banda-García LI; Rodríguez-Sánchez V; Meillón-García LA; Urbina-Escalante E; Martínez-Ramírez MA; Loera-Fragoso SJ; Martínez-Coronel J; Zapata-Canto N; Gómez-Cortés SC; Medina-Coral JE; Mójica-Balderas L; Pérez-Zúñiga JM; Pérez FJ; López-Arroyo JL; Zazueta-Pozos JF; Romero-Martínez E; Romero-Rodelo H; Tapia-Enríquez AL; Soriano-Mercedes EJ; Salazar-Ramírez Ó; Vilchis-González SP; Tepepa-Flores F; Alvarado-Ibarra M
Gac Med Mex; 2022; 158(Supl 1):26-37. PubMed ID: 37734057
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Fedratinib in Myelofibrosis.
Waksal JA; Tremblay D; Mascarenhas J
Onco Targets Ther; 2021; 14():4509-4521. PubMed ID: 34456572
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutics and targets in myelofibrosis.
Waksal JA; Harrison CN; Mascarenhas JO
Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapeutic options for myelofibrosis: a Canadian perspective.
Gupta V; Foltz L; Sirhan S; Busque L; Turner AR
Am J Blood Res; 2012; 2(3):170-86. PubMed ID: 23119228
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutics for myelofibrosis.
Lee SE
Blood Res; 2023 Apr; 58(S1):S13-S19. PubMed ID: 36891574
[TBL] [Abstract][Full Text] [Related]
14. Emerging Treatment Options for Myelofibrosis: Focus on Anemia.
Sastow D; Tremblay D
Ther Clin Risk Manag; 2023; 19():535-547. PubMed ID: 37404252
[TBL] [Abstract][Full Text] [Related]
15. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
Morsia E; Gangat N
Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
[No Abstract] [Full Text] [Related]
16. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562644
[TBL] [Abstract][Full Text] [Related]
17. ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.
Duminuco A; Chifotides HT; Giallongo S; Giallongo C; Tibullo D; Palumbo GA
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201581
[TBL] [Abstract][Full Text] [Related]
18. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
[TBL] [Abstract][Full Text] [Related]
19. The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.
Marcellino BK; Verstovsek S; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):415-421. PubMed ID: 32199764
[TBL] [Abstract][Full Text] [Related]
20. Standard care and investigational drugs in the treatment of myelofibrosis.
Barraco D; Maffioli M; Passamonti F
Drugs Context; 2019; 8():212603. PubMed ID: 31645880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
